Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver
disease globally and is currently estimated to affect 38% of the global population. Only a …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Background & Aims The increasing rates of obesity and type 2 diabetes mellitus may lead to
increased prevalence of nonalcoholic fatty liver disease (NAFLD). We aimed to determine …

Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Background Studies have reported a significant association between non-alcoholic fatty liver
disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the …